TAK — Takeda Pharmaceutical Company Limited

Takeda Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: JPY 3.4 trillion for the nine-month period, down 3.3% year-on-year (2.8% decline at constant exchange rates).
• Core Operating Profit: JPY 971.6 billion, a decrease of 3.4% year-on-year.
• Reported Operating Profit: JPY 422.4 billion, an increase of 1.2%.
• Core EPS: JPY 428; Reported EPS: JPY 137.
• Adjusted Free Cash Flow: Strong at JPY 625.9 billion, despite a USD 1.2 billion upfront payment to Innovent Biologics.
• Growth Products: Over 50% of total revenue, grew 6.7% at constant exchange rates.

2. Strategic Updates and Business Highlights

• Pipeline Focus: Takeda is preparing for significant new product launches, particularly oveporexton (narcolepsy), rusfertide (polycythemia vera), and zasocitinib (psoriasis), expected to launch within the next 18 months.
• Regulatory Filings: New drug applications for oveporexton and rusfertide have been submitted to the FDA.
• ENTYVIO Performance: Strong growth of 7.4% at constant exchange rates, with improved coverage among major pharmacy benefit managers.
• Pipeline Expansion: Additional innovative programs added through a partnership with Innovent Biologics.

3. Forward Guidance and Outlook

• Full-Year Revenue Guidance: Revised to a low single-digit decline at constant exchange rates, primarily due to VYVANSE generic erosion.
• Core OP and EPS Guidance: Maintained; core OP forecast at JPY 1.15 trillion and core EPS at JPY 486.
• Cash Flow Forecast: Upgraded, reflecting strong operational performance and cost management.

4. Bad News, Challenges, or Points of Concern

• VYVANSE Generic Erosion: Significant impact on revenue, though the decline is tapering off.
• Competition: New entrants in the market are affecting growth rates for TAKHZYRO and ENTYVIO.
• Market Dynamics: Potential price cuts from the IRA negotiations could impact ENTYVIO's peak sales projections.
• R&D Investment Pressure: Increased spending anticipated for upcoming product launches, which may affect short-term profitability.

5. Notable Q&A Insights

• ENTYVIO Sales: Analysts questioned whether the strong Q3 performance could continue, with Takeda expressing confidence in achieving its growth guidance.
• IRA Impact on ENTYVIO: Takeda is preparing for potential price negotiations but remains cautious about the implications for future sales.
• Zasocitinib Launch Timeline: Regulatory submission expected in summer 2025, with potential for earlier launch than the projected 18 months.
• TAKHZYRO Market Share: Slowing growth attributed to competitive pressures and Medicare Part D redesign impacting demand.

Overall, Takeda's Q3 results reflect a mix of solid operational performance and strategic advancements in its pipeline, tempered by challenges from competitive pressures and regulatory uncertainties. The company is focused on maintaining growth while preparing for significant product launches in the near future.